Shannon L Maude Selected Research

Cytokines

10/2020	Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children.
1/2016	Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy.
1/2016	Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.
3/2014	Managing cytokine release syndrome associated with novel T cell-engaging therapies.
6/2013	Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shannon L Maude Research Topics

Disease

42	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 02/2024 - 08/2012
18	Cytokine Release Syndrome 01/2023 - 06/2013
16	Neoplasms (Cancer) 01/2023 - 02/2005
9	Leukemia 01/2023 - 10/2012
4	Residual Neoplasm 02/2024 - 12/2020
3	Infections 01/2023 - 01/2020
3	Sepsis (Septicemia) 01/2022 - 02/2014
3	Hemophagocytic Lymphohistiocytosis (Hemophagocytic Syndrome) 01/2022 - 06/2013
3	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 01/2016
3	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 10/2021 - 11/2017
3	Critical Illness (Critically Ill) 10/2020 - 01/2016
2	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2022 - 01/2018
2	cell-associated neurotoxicity 01/2022 - 12/2020
2	Fever (Fevers) 10/2021 - 02/2017
2	Bites and Stings (Sting) 01/2018 - 06/2013
2	Hyperferritinemia 02/2017 - 06/2013
1	COVID-19 01/2023
1	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 01/2022
1	Lymphoma (Lymphomas) 01/2022
1	Prostatic Neoplasms (Prostate Cancer) 01/2022
1	Down Syndrome (Down's Syndrome) 01/2022
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 12/2021
1	Central Nervous System Diseases (CNS Diseases) 10/2021
1	Agammaglobulinemia (Hypogammaglobulinemia) 01/2020
1	Philadelphia Chromosome 01/2019
1	Glucocorticoid Receptor Deficiency 01/2019
1	Multiple Myeloma 01/2018
1	Respiratory Insufficiency (Respiratory Failure) 02/2017
1	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 02/2017
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2017
1	Body Weight (Weight, Body) 10/2014
1	Macrophage Activation Syndrome 03/2014
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 02/2014
1	Cytopenia 06/2013
1	Carcinogenesis 04/2006
1	Genomic Instability 04/2006

Drug/Important Bio-Agent (IBA)

33	Chimeric Antigen ReceptorsIBA 12/2023 - 10/2014
22	tisagenlecleucelIBA 02/2024 - 10/2014
5	tocilizumab (atlizumab)FDA Link 01/2022 - 10/2014
5	CytokinesIBA 10/2020 - 06/2013
4	AntibodiesIBA 01/2022 - 06/2013
3	blinatumomabIBA 01/2022 - 06/2013
3	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2016
3	Interleukin-6 (Interleukin 6)IBA 01/2022 - 03/2014
3	Immunoglobulins (Immunoglobulin)IBA 01/2021 - 01/2018
2	EmapalumabIBA 01/2023 - 01/2022
2	Immunoconjugates (Immunoconjugate)IBA 01/2022 - 01/2018
2	siltuximabIBA 01/2022 - 01/2016
2	CD19-specific chimeric antigen receptorIBA 01/2020 - 01/2016
2	Cytokine Receptors (Cytokine Receptor)IBA 01/2019 - 08/2012
2	Phosphotransferases (Kinase)IBA 01/2019 - 08/2012
2	CD19 AntigensIBA 12/2015 - 12/2014
2	Cyclin-Dependent Kinases (cdk Proteins)IBA 04/2006 - 02/2005
1	Oxygen (Dioxygen)IBA 01/2023
1	Prostate-Specific Antigen (Semenogelase)IBA 01/2022
1	GlucocorticoidsIBA 01/2022
1	Blood Proteins (Serum Proteins)IBA 01/2022
1	ProteomeIBA 01/2022
1	Methylprednisolone FDA LinkGeneric 01/2022
1	Proteins (Proteins, Gene)FDA Link 01/2022
1	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2022
1	Inotuzumab OzogamicinIBA 01/2022
1	Anaplastic Lymphoma KinaseIBA 01/2022
1	Death Domain ReceptorsIBA 01/2020
1	Immunoglobulin G (IgG)IBA 01/2020
1	AntigensIBA 01/2020
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2019
1	daratumumabIBA 01/2018
1	Monoclonal AntibodiesIBA 01/2018
1	Ferritins (Ferritin)IBA 02/2017
1	Surface Antigens (Surface Antigen)IBA 01/2017
1	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 01/2016
1	EpitopesIBA 12/2015
1	InterferonsIBA 03/2014
1	InterleukinsIBA 03/2014
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 06/2013
1	Sirolimus (Rapamycin)FDA Link 10/2012
1	ruxolitinibIBA 10/2012

Therapy/Procedure

31	Therapeutics 12/2023 - 04/2006
11	Immunotherapy 01/2022 - 01/2016
8	Drug Therapy (Chemotherapy) 01/2024 - 02/2005
3	Critical Care (Surgical Intensive Care) 01/2023 - 02/2014
1	Secondary Prevention 02/2024
1	Castration 01/2022
1	Retreatment 01/2021
1	Artificial Respiration (Mechanical Ventilation) 02/2017